225Ac-DOTA-LM3 Research for Gastroenteropancreatic NETs
An evidence-based overview of research examining 225Ac-DOTA-LM3 in the context of gastroenteropancreatic nets. This page synthesizes findings from peer-reviewed literature.
Research Summary
GEP-NETs represent the most studied indication for SSTR-targeted PRRT. Following progression on Lutathera (Lu-177 DOTATATE), 225Ac-DOTA-LM3 offers a salvage option with different mechanism of cell killing. Clinical data shows disease stabilization in majority of refractory patients.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. 225Ac-DOTA-LM3 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.